OAC
NVCT icon

OMERS Administration Corp’s Nuvectis Pharma NVCT Stock Holding History

OMERS Administration Corp’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32,882
Closed -$321K – 1029
2025
Q1 		$321K Buy
+32,882
New +$237K ﹤0.01% 845

Other funds holding NVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

OMERS Administration Corp's NVCT Position: Q2 2025 in Review

OMERS Administration Corp sold out of Nuvectis Pharma (NVCT) in Q2 2025, closing a stake of 32,882 shares — an estimated $321K sold.

OMERS Administration Corp first reported a position in NVCT in Q1 2025 and held it in 1 quarter. The position peaked at $321K in Q1 2025. 47 funds tracked by Wall St. Rank hold NVCT as of Q2 2025.

  • OMERS Administration Corp reported no remaining Nuvectis Pharma position as of Q2 2025 after selling out during the quarter.
  • OMERS Administration Corp sold 32,882 Nuvectis Pharma shares in Q2 2025, an estimated $321K.
  • OMERS Administration Corp first reported a position in Nuvectis Pharma in Q1 2025 and held it in 1 quarter.
  • OMERS Administration Corp's Nuvectis Pharma position peaked at $321K in Q1 2025.
  • 47 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2025.

Based on OMERS Administration Corp's 13F filing for Q2 2025, filed 13 Aug 2025.